Q32 Bio Inc.
QTTB
Get informed when a big investor buys or sells
+ FollowMarket Cap$109.52M
Close$
$3.94
49.3% downside
Current Fair Value
49.3% downsideOvervalued by 49.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $109.52 Million |
|---|---|
| Enterprise Value | $7.81 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.42 |
| Beta | -0.33 |
| Outstanding Shares | 14,095,371 |
Return
| Return on Equity | 31.90% |
|---|---|
| Return on Assets | 29.16% |
| Return on Invested Capital | 19.67% |
Valuation & Multiples
| P/E Ratio | 2.99 |
|---|---|
| PEG | -52.24 |
| Price to Sales | 2.59 |
| Price to Book Ratio | 1.11 |
| Enterprise Value to Revenue | 0.15 |
| Enterprise Value to EBIT | 0.36 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.58 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
$1.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 261,300▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 157.35%▲ 90.46% |
|---|---|
| Total Invested | $282.56M▲ 366.14% |
| Investors Holding | 73▲ 20.00% |
ESG Score
No data
About Q32 Bio Inc.
131 employees
CEO: Arthur Tzianabos homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.